Kiora Pharmaceuticals

Historical price data

Kiora Pharmaceuticals is a clinical-stage biotech focused on developing advanced small molecule therapies for retinal diseases with high unmet need. Its strategy is built on two distinct platforms: KIO-301, a first-in-class 'photoswitch' molecule designed to restore vision in inherited retinal diseases by converting dormant retinal cells into light sensors, and KIO-104, an immune modulator for inflammatory conditions like proliferative vitreoretinopathy (PVR). The company has achieved key regulatory milestones, including Orphan Drug designations for both lead assets, and is advancing its pipeline through strategic partnerships and clinical trials.

Two proprietary small molecule platforms: 1) KIO-301 'photoswitch' molecules designed to convert dormant retinal cells into light sensors for inherited retinal diseases, and 2) KIO-104 DHODH inhibitors for localized immune modulation in retinal inflammatory conditions.

In IRDs, Kiora's mutation-agnostic KIO-301 differentiates from mutation-specific gene therapies but competes with other optogenetic approaches and retinal implants. In PVR, KIO-104's primary competition is the absence of any approved drug (surgery only), though off-label anti-inflammatories are used. Its targeted DHODH inhibition offers a novel mechanism versus broad immunosuppressants.